Physician profile
Michael A Johnson
NPI 1548203185
$8,503.52
in general payments reported to CMS, 2019-2025
21 companies · $691 in 2025
The $691 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.00 · 2020: $413 · 2021: $874 · 2022: $5,533 · 2023: $659 · 2024: $268 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,617.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $6,414.24 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $400.47 | 2022-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $275.35 | 2020-2023 | Vabysmo |
| Eyepoint US, INC. | $182.19 | 2023 | |
| Harrow Eye, LLC | $179.19 | 2025 | Iheezo |
| Apellis Pharmaceuticals, INC. | $169.73 | 2025 | Syfovre |
| Genentech, INC. | $150.00 | 2023 | Vabysmo |
| Alcon Vision LLC | $124.45 | 2025 | Constellation |
| Boston Scientific Corporation | $109.04 | 2024 | |
| Allergan, INC. | $96.50 | 2019-2022 | |
| Coherus Oncology, INC. | $73.41 | 2023 | |
| Optos, INC. | $62.65 | 2021 | |
| Biogen, INC. | $46.47 | 2022 | |
| Novartis Pharmaceuticals Corporation | $41.83 | 2021 | |
| Bausch & Lomb Americas INC. | $39.10 | 2023-2025 | Xipere, Visudyne, Lotemax Sm |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dutch Ophthalmic, USA | $37.76 | 2021 | |
| Mallinckrodt Hospital Products INC. | $27.52 | 2022 | |
| Ocular Therapeutix, INC. | $24.17 | 2025 | Dextenza |
| Novo Nordisk INC | $17.11 | 2020 | |
| Abbvie INC. | $16.86 | 2022 | |
| Sandoz INC. | $15.48 | 2024 | Cimerli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$18,750.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.